The Estée Lauder Companies Announces Brand Leadership Promotions
1.7.2021 15:30:00 EEST | Business Wire | Press release
The Estée Lauder Companies (NYSE:EL) announced today the promotions of two brand leaders – Michelle Freyre has been promoted to Global Brand President, Clinique, and Glenn Evans has been promoted to Global Brand President, Smashbox and GLAMGLOW. The promotions are effective July 1, 2021, and both leaders will continue to report directly to John Demsey, Executive Group President, The Estée Lauder Companies (ELC).
“Michelle and Glenn are both incredibly dynamic leaders who have beautifully steered their respective brands through the challenges of the past year,” said John Demsey. “I am particularly proud of how effectively they have balanced the needs of the business while being truly thoughtful and empathetic leaders to their brand teams. Their promotions are both very well-deserved.”
Michelle Freyre Has Been Promoted to Global Brand President, Clinique
A dynamic leader with deep experience leading a variety of beauty brands across categories and channels, Michelle’s promotion to Global Brand President, Clinique, recognizes her outstanding and visionary leadership in returning Clinique to global growth. She was appointed Senior Vice President/Global General Manager, Clinique in June 2020, and since then has made a significant impact on Clinique’s brand positioning, driving double digit growth for hero products, as well as redefining the innovation strategy behind Clinique’s hero franchises. She has also driven Clinique’s acceleration in Online to be the #1 ELC brand in North America in that channel, while delivering the Clinique High-Touch experience at scale globally. Her inspirational leadership, deep expertise in beauty and skin care, together with her strong passion for connecting with global consumers, makes her uniquely suited to continue to lead Clinique in its next chapter of growth.
Michelle joined ELC from Johnson & Johnson in 2020, where she had an impressive 20-year career holding various leadership roles within its Consumer Health Products division, most recently serving as President, U.S. Beauty. In this role, she was responsible for the company’s portfolio of Beauty brands at the time, and led the successful performance and growth of many brands. Prior to that, she served as the General Manager of Neutrogena at J&J, and as the leader of the company’s Los Angeles campus.
Michelle is passionate about talent development and has a proven track record of fostering workplaces that embrace inclusion and diversity. She has received several industry awards and honors in recognition of her exceptional career, including being named to Fortune’s 2018 “50 Most Powerful Latinas in Business.”Michelle is the Executive Sponsor of Hispanic Connections (HiC) ERG and is actively mentoring diverse talent across ELC.
Glenn Evans Has Been Promoted to Global Brand President, Smashbox and GLAMGLOW
With more than 30 years of strategic, operational and brand-building experience, Glenn is an exceptional, values-driven brand leader with an impressive track record of delivering consistent results. As Senior Vice President/Global General Manager, Smashbox and GLAMGLOW, Glenn has successfully led both brands, capturing operational and supply chain synergies between them, optimizing their global brand and regional go-to-market structures and improving A&P effectiveness.
As Global Brand President, Glenn will continue to lead Smashbox and GLAMGLOW into their next phases of sustainable growth, focusing on product innovations with a consumer-led, online-centric, digital-first approach, as well as continuous transformation to evolve ahead of the changing retail landscape. A dynamic and energetic leader, Glenn will also continue to leverage his passion for developing top talent across both brand teams.
Since being named Senior Vice President and General Manager, Smashbox, in 2019, Glenn has led the brand’s repositioning strategy to drive appeal with both new and loyal consumers while staying true to the brand’s core studio heritage. Under his leadership, the brand reinforced its number one ranking in U.S. prestige Face Primers, achieved top rankings in prestige Face Primers in key global markets, and attracted new consumers with the success of Smashbox Halo All-in-One Tinted Moisturizer.
Before his role at Smashbox, Glenn was Senior Vice President, Leading Beauty Forward, where he led the successful global implementation of Leading Beauty Forward and OneSource, which have helped to fuel the company’s multiple engines of growth strategy. Prior to that role, Glenn was SVP, Global Supply Chain, during which time he established and led the Global Supply Chain Center of Excellence for six years, and played a leadership role in integrating and enhancing best-in-class capabilities across the organization.
Since 2018, Glenn has served as an Executive Sponsor of wELCome, ELC’s Employee Resource Group for LGBTQIA+ employees. He continues to act as a passionate advocate for Inclusion & Diversity across the Company. Glenn recently announced the creation of the West Coast chapter of wELCcome and he also sponsors the Smashbox & GLAMGLOW Multi-Ethnic Advisory Board, an employee-led group within the brands that aims to ensure diverse voices are amplified during key moments of decision-making.
About The Estée Lauder Companies Inc.
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers and marketers of quality skin care, makeup, fragrance and hair care products. The company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, Tommy Hilfiger, M·A·C, La Mer, Bobbi Brown, Donna Karan New York, DKNY, Aveda, Jo Malone London, Bumble and bumble, Michael Kors, Darphin Paris, TOM FORD BEAUTY, Smashbox, Ermenegildo Zegna, AERIN, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, BECCA, Too Faced and Dr.Jart+, and the DECIEM family of brands, including The Ordinary and NIOD.
ELC-C
ELC-L
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210701005234/en/
Contact information
Investor Relations:
Rainey Mancini
(212) 284-3049
rmancini@estee.com
Media Relations:
Jill Marvin
(212) 572-4438
jimarvin@estee.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
